Related Experiment Video
Updated: Jun 13, 2026

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
Aspects of beta-amyloid as a biomarker for Alzheimer's disease
Ulf Andreasson1, Erik Portelius, Malin E Andersson
1Sahlgrenska University Hospital/Mölndal, Clinical Neurochemistry Laboratory/Mölndal, S-431 80, Göteborg University, Mölndal, Sweden.
Abstract:
Alzheimer's disease is an age-related neurodegenerative disorder that results in progressive cognitive impairment and death. The accumulation of beta-amyloid (Abeta) in specific brain regions is believed by many to represent the earliest event in the pathogenesis of the disease. Here, we review the key aspects of Abeta as a biomarker for Alzheimer's disease, including the pathogenicity of Abeta, the possible biological functions of its precursor protein, the Abeta metabolism and homeostasis, the diagnostic performance of different Abeta assays in different settings and the potential usefulness of Abeta as a surrogate marker for treatment efficacy in clinical trials of novel Abeta-targeting drugs against Alzheimer's disease.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease l: Introduction
Dementia l: Introduction